抗肿瘤药物相关性间质性肺疾病诊断和治疗专家共识
Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease.
机构信息
Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, 100029, China.
Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 10021, China.
出版信息
Curr Med Sci. 2023 Feb;43(1):1-12. doi: 10.1007/s11596-022-2693-2. Epub 2023 Mar 3.
Drug-induced interstitial lung disease (DILD) is the most common pulmonary adverse event of anticancer drugs. In recent years, the incidence of anticancer DILD has gradually increased with the rapid development of novel anticancer agents. Due to the diverse clinical manifestations and the lack of specific diagnostic criteria, DILD is difficult to diagnose and may even become fatal if not treated properly. Herein, a multidisciplinary group of experts from oncology, respiratory, imaging, pharmacology, pathology, and radiology departments in China has reached the "expert consensus on the diagnosis and treatment of anticancer DILD" after several rounds of a comprehensive investigation. This consensus aims to improve the awareness of clinicians and provide recommendations for the early screening, diagnosis, and treatment of anticancer DILD. This consensus also emphasizes the importance of multidisciplinary collaboration while managing DILD.
药物性间质性肺疾病（DILD）是抗肿瘤药物最常见的肺部不良反应。近年来，随着新型抗肿瘤药物的快速发展，抗肿瘤 DILD 的发病率逐渐增高。由于临床表现多样，缺乏特异性诊断标准，DILD 诊断困难，如处理不当甚至可致命。为此，我国肿瘤、呼吸、影像、药理、病理和放射等多学科专家进行了多次全面调研，达成《抗肿瘤药物 DILD 诊断与治疗专家共识》。旨在提高临床医生对 DILD 的认识，为抗肿瘤 DILD 的早期筛查、诊断和治疗提供建议，并强调多学科协作在 DILD 管理中的重要性。
Zotero 插件